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Highly active antiretroviral therapy (HAART) alone can-
not eliminate HIV from the body and even in patients
with undetectable viral load, full recovery of the immune
system is not being obtained, with signs of inappropriate
“immune activation” and “immuno-senescence”.T h e r a -
peutic strategies, complementary to HAART, aim at a
“functional cure” i.e. control HIV in such a way that it
no longer produces harm to the immune system. Anti-
latency drugs, anti-inflammatory agents and/or measures
to prevent or eliminate concomitant infections may con-
tribute to a functional cure. Immunotherapy represents
another possible strategy, which should reverse deficient
T cell generation, aberrant differentiation, exhaustion
and ineffective HlV-specific T cell responses.
Four major pathways are being attempted:
1. Administration of so called common g-chain cyto-
kines, including inter-leukin (IL)-2, IL-7, IL-15 or IL-21,
which are crucial in T cell generation, differentiation
and function. Only IL-2 has been formally evaluated in
a phase 3 trial: although it increased CD4 T counts, it
failed to improve clinical outcome.
2. Blockade of negative regulator receptor-ligand inter-
action, including CTLA-4, PD-1, TIM-3 has been shown
to improve HlV-specific T cell function in vitro, but see-
mingly discrepant results have been obtained in the SIV
macaque model. PD-1 blockade lowered viral load and
improved survival, whereas CTLA-4 blockade increased
viral load, probably because of immune activation.
3. Therapeutic immunization with HIV antigens.
Older trials with de-enveloped HIV particles (Remune
®)
failed to improve clinical outcome in HIV-infected sub-
jects. More recent trials, using ALVAC
®,ac a n a r y p o x
vaccine, containing HIV antigens-encoding genes, miti-
gated viral load rebound after HAART interruption in
several trials, but had no effect or even increased
rebound in other trials, the latter result being probably
linked to inappropriate immune activation.
4. The most recent tendency is to target dendritic cells
with either inactivated autologous virus or virus antigen-
encoding RNA. Safety and ímmunogenicity of this strat-
egy has been well established, but clinical results are
equivocal as yet. In any case, this approach is amendable
to further refinement, with regard to inclusion of RNA
encoded patient-adapted viral sequences and co-stimula-
tory molecules, as well as improved targeting.
In conclusion, several HIV immunotherapy strategies
are being attempted, with varying success. The basic
challenge remains to find a (combined) strategy, suc-
cessfully activating effective HlV-specific T cell
responses, while reducing inappropriate HIV-promoting
immune activation.
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